Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm

Samsung Biologics reported that it has inked a $262 million manufacturing agreement with an unnamed European pharmaceutical company. The deal includes manufacturing commitments, which will be conducted at Samsung Biologics’ Songdo manufacturing site in South Korea extending through 2033.

A Samsung Biologics’ spokesperson stated that the company’s cumulative contract value surpasses $21.9 billion following the latest agreement.

The company currently operates 845 kL of manufacturing capacity across Korea and the U.S., including 785 kL in Songdo and 60 kL at its Rockville, MD site. Acquired in March 2026, the Rockville facility established Samsung Biologics’ first manufacturing presence in the U.S., expanding the company’s global production network. Officials at Samsung Biologics say the company is also strengthening its regional presence through offices in NJ, Boston, Tokyo, and Amsterdam.

Samsung has secured land for Bio Campus III, establishing the foundation for its next phase of long-term capacity and capability expansion. The planned campus is expected to support dedicated R&D and manufacturing programs for next-generation therapeutics while the company continues to evaluate additional capacity investments in line with long-term market demand and client requirements.

Alongside capacity expansion, Samsung Biologics announced that it is pursuing opportunities to broaden its portfolio and address an increasingly diverse range of therapeutic modalities. The company has announced an all-cash offer to acquire PolyPeptide Group, which is expected to expand Samsung Biologics’ capabilities into peptide-based therapeutics and further diversify its global manufacturing network, subject to the completion of the proposed transaction.

The post Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm appeared first on GEN - Genetic Engineering and Biotechnology News.